JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brooks, D. P.
Right arrow Articles by Kinter, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brooks, D. P.
Right arrow Articles by Kinter, L. B.

SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta)

DP Brooks, PF Koster, CR Albrightson-Winslow, FL Stassen, WF Huffman and LB Kinter

Department of Pharmacology, Smith Kline & French Laboratories, King of Prussia, Pennsylvania 19406-0939.

The vasopressin analog desGly(CH2)5D-Tyr(Et)VAVP (SK&F 101926) is a potent antagonist of the antidiuretic action of vasopressin in rats, dogs, and squirrel monkeys, demonstrating minimal agonist activity in these species. In humans, however, SK&F 101926 was a potent full antidiuretic agonist. This agonist response was not predicted by in vitro studies with human tissue. The purpose of the present study was to determine if the agonist activity of SK&F 101926 could be modeled in an old-world primate, the rhesus monkey, and, if agonist activity was demonstrated, to determine how SK&F 101926 could be modified to reduce agonist activity and permit the elaboration of antagonist activity in that species. We observed that i.v. administration of SK&F 101926 to the hydrated rhesus monkey resulted in a full antidiuretic agonist response, as observed in humans, and did not reduce urine osmolality or increase urine flow when administered to hydropenic rhesus monkeys. Changing the terminal amino acids from Pro7, Arg8 to Arg7, D-Arg8 produced a compound (SK&F 104146) that was also an agonist, although less potent than SK&F 101926. Further substitution in SK&F 104146 of the sulfide groups of cysteine residues with methyl groups in the peptide ring to produce a "dicarba bridge" resulted in a compound (SK&F 105494) that was associated with minimal agonist activity in hydrated monkeys. Administration of SK&F 105494 (30 micrograms/kg i.v.) reduced urine osmolality from 629 +/- 20 to 91 +/- 7 mosmol/kg H2O (P less than .01) and increased free water clearance to positive levels (from -0.16 +/- 0.03 to 0.73 +/- 0.18 ml/min; P less than .05) in anesthetized hydropenic monkeys.

Volume 245, Issue 1, pp. 211-215, 04/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Yamamura, S. Nakamura, S. Itoh, T. Hirano, T. Onogawa, T. Yamashita, Y. Yamada, K. Tsujimae, M. Aoyama, K. Kotosai, et al.
OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats
J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 860 - 867.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. P. Brooks, M. Valente, G. Petrone, P. D. Depalma, M. Sbacchi, and G. D. Clarke
Comparison of the Water Diuretic Activity of Kappa Receptor Agonists and a Vasopressin Receptor Antagonist in Dogs
J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1176 - 1183.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics.